Sugammadex
16
1
2
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 16 trials
100.0%
+13.5% vs benchmark
31%
5 trials in Phase 3/4
13%
1 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (16)
NMBA Reversal and Postoperative Urinary Retention
Sugammadex-Induced Clenching During Neuromuscular Blockade Reversal
Comparison of the Effects of Sugammadex and Neostigmine on Early Extubation, Intensive Care Unit Admission and Length of Stay, and Hospital Costs in Adult Cranial Surgery
Quantitative Neuromuscular Monitoring and Gastric Bypass Surgery
Sugammadex on Laparoscopic Bariatric Surgery
Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex
Sugammadex and Time to Extubation in Ophthalmic Surgery
Effectiveness on Smooth Extubation According to the Administration Time of Sugammadex
Neostigmine Versus Sugammadex on Renal Functions
Effect of Muscle Relaxation Reversal on the Success Rate of Motor Evoked Potential Recording
Comparative Efficacy and Safety of Sugammadex and Neostigmine
Residual Paralysis and Reversal With Routine Neostigmine Versus Half-dose Sugammadex and Routine Neostigmine
Diaphragm Ultrasound to Evaluate the Antagonistic Effect of Sugammadex
The Effect of Sugammadex During Transcranial Electrical Motor Evoked Potential Monitoring in Spinal Surgery
Comparison of QoR-15 in Laparoscopic Cholecystectomy: Sugammadex vs. Neostigmine
Effectiveness of Sugammadex on Muscle Relaxant Reversal in Preterm Neonates